

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

## **ADDITIONAL RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING**

This announcement is made by TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of the Company dated 2 April 2024, 18 April 2024, 5 June 2024, 27 June 2024, 28 June 2024, 31 July 2024, 30 September 2024, 4 October 2024, 3 January 2025 and 31 March 2025 in relation to, among other things, the resumption guidance imposed by the Stock Exchange on the Company (the “**Initial Resumption Guidance**”) and quarterly updates on resumption progress (collectively, the “**Resumption Guidance and Quarterly Update Announcements**”); (ii) the announcements of the Company dated 19 June 2025, 27 June 2025 and 8 July 2025 in relation to, among others, resignation of Directors (the “**Resignation Announcement(s)**”); and (iii) the announcement of the Company dated 8 July 2025 in relation to, among others, appointment of Directors (the “**Appointment Announcement**”, together with the Resumption Guidance and Quarterly Update Announcements and the Resignation Announcements, collectively, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

## ADDITIONAL RESUMPTION GUIDANCE

As disclosed in the Resignation Announcement dated 19 June 2025, following the resignation of Mr. Tao Chi Keung (“**Mr. Tao**”) as an independent non-executive Director with effect from 13 June 2025, (i) the number of independent non-executive Directors fell below the minimum number as required under Rule 3.10(1) of the Listing Rules; (ii) the number of members of the Audit Committee fell below the minimum number as required under Rule 3.21 of the Listing Rules; and (iii) the number of members of each of the Audit Committee and the Remuneration Committee fell below the minimum number as required under the respective terms of reference of the Audit Committee and the Remuneration Committee. Accordingly, the Company was not in compliance with Rules 3.10(1) and 3.21 of the Listing Rules.

On 20 June 2025, the Company received a letter from the Stock Exchange setting out additional guidance for the resumption of trading in the Shares on the Stock Exchange (the “**Additional Resumption Guidance**”, together with the Initial Resumption Guidance, collectively, the “**Resumption Guidance**”):

- re-comply with Rules 3.10(1) and 3.21 of the Listing Rules.

The Stock Exchange also indicated that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

As further disclosed in the Appointment Announcement, two new non-executive Directors, namely, Mr. Zhang Ming Qi and Mr. Chen Qi and three new independent non-executive Directors, namely, Mr. Li Liang, Ms. Huang Lin and Mr. Du Jianfeng had been appointed to the Board, all with effect from 23 June 2025.

Following the appointment of Mr. Li, Ms. Huang and Mr. Du as independent non-executive Directors and members of each of the Audit Committee, Remuneration Committee and nomination committee (the “**Nomination Committee**”) of the Company, (i) there are at least three independent non-executive Directors on the Board; (ii) the Audit Committee comprises four members, all of whom are independent non-executive Directors; (iii) the Remuneration Committee comprises four members, all of whom are independent non-executive Directors; and (iv) the Nomination Committee comprises four members, all of whom are independent non-executive Directors. Accordingly, the Company has re-complied with the requirements under Rules 3.10(1) and 3.21 of the Listing Rules as well as the requirements under the respective terms of reference of the Audit Committee, Remuneration Committee and Nomination Committee as at the date of this announcement.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the Resumption Guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**TATA Health International Holdings Limited**  
**Zhang Ming Qi**  
*Non-executive Director*

Hong Kong, 11 July 2025

*As at the date of this announcement, the Board comprises four non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and four independent non-executive Directors, namely, Mr. Wang Jian, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.*